PEDIATRIC ONCOLOGY GROUP PARTICIPATION

儿科肿瘤小组参与

基本信息

批准号：
2633742
负责人：
CHING-HON PUI
金额：
$ 45.78万
依托单位：
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
1982
资助国家：
美国
起止时间：
1982-01-01 至 2000-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/2633742
关键词：
6 thiopurine Ewing's tumor Hodgkin's disease Wilms' tumor XomaZyme acivicin acute leukemia acute lymphocytic leukemia acute myelogenous leukemia adolescence (12-20) antineoplastics asparaginase astrocytoma biological response modifiers bone marrow transplantation brain neoplasms cancer registry /resource cancer risk central nervous system neoplasms child (0-11) chronic myelogenous leukemia cis platinum compound clinical research clinical trial phase I colony stimulating factor combination cancer therapy combination chemotherapy cooperative study cyclophosphamide cyclosporines cytosine arabinoside daunorubicin deferoxamine deoxycoformycin doxorubicin drug screening /evaluation enalapril ependymoma etoposide fazarabine fluorouracil germ cell neoplasms glioma hepatoblastoma hepatocellular carcinoma human genetic material tag human immunodeficiency virus 1 human subject human therapy evaluation human tissue ifosfamide interferons interleukin 2 medulloblastoma melphalan metastasis methotrexate mitoxantrone molecular oncology neoplasm /cancer chemotherapy neoplasm /cancer classification /staging neoplasm /cancer epidemiology neoplasm /cancer genetics neoplasm /cancer immunology neoplasm /cancer immunotherapy neoplasm /cancer pharmacology neoplasm /cancer radiation therapy neoplasm /cancer relapse /recurrence neoplasm /cancer surgery neuroblastoma nonHodgkin's lymphoma osteosarcoma paclitaxel pediatric pharmacology podophyllin prednisone retinoate rhabdomyosarcoma tissue resource /registry topotecan trimetrexate vincristine

项目摘要

We propose continued participation in the Pediatric Oncology Group (POG). Our goals are as follows: (1) to improve cure rates for children with cancer through participation in Phase I, II, and III clinical trials designed to test new agents or concepts; and (2) to participate in laboratory-based research aimed at clarifying the basis of drug resistance and pathogenetic mechanisms of childhood cancers. We are committed to Group participation because we believe: (1) that collaborative efforts are both desirable and necessary for study of childhood cancers, since all are relatively rare; and (2) that well-designed randomized clinical trials provide the most definitive test of efficacy and general applicability of new therapies and that pooled intellectual resources are advantageous as well. Our contribution to the Group can be categorized as follows: (1) contribution of selected patients (those with rare tumors or less common stages of other cancers, n approximately 80-100/year) to Group studies; (2) administrative and scientific leadership (e.g., disease or discipline committee chairs, and protocol coordinators); (3) provision of multiple reference laboratories (flow cytometry analyses of leukemia and solid tumors, cell bank, AML cytogenetics, pharmacokinetics/pharmacodynamics, molecular genetics of leukemia and solid tumor); (4) regular presentation of results of in-house research to the group. Since our center has an unusually large number of patients and staff (both clinical and basic), the latter contribution assumes unusual importance. We have an extensive in-house developmental therapeutics program which is independent of, but complementary to, the Group's clinical research programs. We also have extensive programs in basic research. The aim of these programs, to determine the pathogenesis of pediatric neoplasia, is expected to positively influence the Group's central goal -- curing children with cancer.

我们建议继续参与儿科肿瘤学组 (POG)。我们的目标是：（1）提高儿童的治愈率通过参与 I、II 和 III 期临床试验来治疗癌症旨在测试新药物或概念； (2) 参与旨在阐明耐药性基础的实验室研究和儿童癌症的发病机制。我们致力于团体参与是因为我们相信：(1) 协作努力是对于儿童癌症的研究来说既可取又必要，因为所有这些都是相对罕见； (2) 精心设计的随机临床试验提供最明确的功效和普遍适用性测试新疗法和汇集智力资源的优势在于出色地。我们对集团的贡献可分为以下几类： (1) 选定患者（患有罕见肿瘤或不太常见的肿瘤的患者）的贡献其他癌症的分期，n 大约 80-100/年）进行小组研究； (2) 行政和科学领导（例如，疾病或纪律委员会主席和礼宾协调员）； (3) 提供多重参考实验室（白血病和实体瘤的流式细胞术分析）肿瘤、细胞库、AML细胞遗传学、药代动力学/药效学、白血病和实体瘤的分子遗传学）；（四）定期汇报向集团内部研究的结果。由于我们中心有异常大量的患者和工作人员（临床和基础），后一项贡献具有非同寻常的重要性。我们拥有广泛的内部发育治疗计划独立于但与集团的临床研究项目相辅相成。我们还有广泛的基础研究计划。这些计划的目的是确定小儿肿瘤的发病机制，有望积极影响集团的中心目标——治愈儿童癌症。